Published in Hospital Business Week, June 12th, 2005
In this trial, the investigational drug phenoxodiol (PXD) is being administered in conjunction with cisplatin or paclitaxel in an attempt to reverse the acquired resistance of the tumors to those two drugs. Phenoxodiol has not been approved for marketing.
The multicenter trial is being conducted at the Yale - New Haven Hospital, New Haven, Conn., and at the Royal Women's Hospital, Melbourne, Australia.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week